Supplemental Experimental Procedures qPCR Primer Sequences for Expression Analysis

PUMA forward:
5'-CTCAACGCACAGTACGAG -3' reverse:
5'-GTCCCATGATGAGATTGTACAG -3' Gadd45 forward: 5'-TCAGCGCACGATCACTGTC -3' reverse:
5'-CCAGCAGGCACAACACCAC -3' GAPDH forward: 5'-TCATTTCCTGGTATGACAACG -3' reverse:
5'-ATGTGGGCCATGAGGT -3' Fas forward: 5'-TCTGCCATAAGCCCTGT -3' reverse:
5'-GTCTGTGTACTCCTTCCCT -3' PMAIP1 (Noxa) forward: 5'-AAGTGCAAGTAGCTGGAAG -3' reverse:
5'-TGTCTCCAAATCTCCTGAGT -3'
MDM2
Forward: 5'-CCAACATGTCTGTACCTACTG -3' Reverse:
5'-TCCGATGATTCCAGGGTC -3' qPCR Primer Sequences for ChIP Analysis PMAIP forward: 5'-GGGAAGTTCTCACTGGAC -3' reverse:
5'-CTGAACACGAACAGTCCT -3' p21 3' forward: 5'-GTCAGCTGCGTTAGAGG -3' reverse:
5'-AGAGGATGGATTGTTCATCTG -3' p21 5' forward: 5'-CCCTCCATCCCTATGCT -3' reverse:
5'-CAGCCTCTTCTATGCCAG -3' Figure S1 .
(A) HCT116 cells were treated with 1μM RITA for the indicated time and subjected to QPCR using MDM2-specific primers. Shown is mean SEM, n = 4.
(B) HCT116 cells were treated like in A, and protein quantified with Western blotting using anti-MDM2 antibody with actin antibody as loading control. HCT116 TP53-/-cells were transfected with siRNA against MDM2 for 48 hr. Protein was measured with Western blotting using antibodies against MDM2 and p21. Actin antibody was used as a loading control. 
